Jae Park, MD

Highlights from the Two-Year Follow-Up Results of the ZUMA-3 Trial

June 28th 2022

An oncologist specializing in the treatment of patients with B-ALL discusses the study design, efficacy, safety, and two-year updated results of the phase I/II ZUMA-3 study evaluating brexucabtagene autoleucel in adult patients with R/R B-ALL.

A Review of Available Treatment Options for Adult Patients with R/R B-ALL

June 28th 2022

Jae Park, MD, shares an overview of available therapeutic options for patients with R/R B-ALL.

Dr. Park on the Dosing Strategies Utilized in the FELIX Trial in R/R ALL

March 10th 2022

Jae Park, MD, discusses dosing strategies utilized in the phase 1/2 FELIX trial in relapsed/refractory acute lymphoblastic leukemia.

Relapsed/Refractory B-Cell ALL: Future Perspectives

February 22nd 2022

Closing thoughts on advances and future perspectives in the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

B-Cell ALL: Integrating Novel Therapies Into Real-World Practice

February 22nd 2022

Expectations regarding where novel therapies such as CAR T-cell therapies will fit into B-cell acute lymphoblastic leukemia treatment algorithms as data from clinical trials continue to evolve.

R/R B-Cell ALL: Is There a Role for Transplantation?

February 22nd 2022

Discussion on the role of transplantation in the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Relapsed/Refractory B-Cell ALL: Adopting MRD Testing into Routine Practice

February 15th 2022

The significance of having novel therapies and molecular tests available to help guide treatment decisions for patients with B-cell acute lymphoblastic leukemia, and recommendations on how to increase the uptake of MRD testing into routine clinical practice.

MRD Assessments in B-Cell ALL

February 15th 2022

When to test for measurable residual disease in B-cell acute lymphoblastic leukemia, and what to keep in mind when selecting a testing method to help assess MRD.

Relapsed/Refractory B-Cell ALL: CAR-T Safety Profiles

February 8th 2022

An overview of adverse events commonly associated with CAR T-cell therapies in relapsed/refractory B-cell acute lymphoblastic leukemia.

CAR-T Therapy for Relapsed/Refractory B-Cell ALL: Sequencing Decisions

February 1st 2022

Recommendations for sequencing CAR T-cell therapies and other key therapies in patients with B-cell acute lymphoblastic leukemia.

CAR T Therapy for Relapsed/Refractory B-Cell ALL: Selecting Appropriate Patients

February 1st 2022

Implications of the ZUMA-3 clinical trial of anti-CD19 CAR T-cell therapy for adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Relapsed Refractory B-Cell ALL: Patient Prognosis

January 25th 2022

Background information regarding the manifestation and prognosis of relapsed/refractory B-cell acute lymphoblastic leukemia.

Dr. Park on Selecting Among Available CAR T-Cell Therapies in MCL

August 5th 2021

Jae Park, MD, discusses the factors to consider when selecting among the available CAR T-cell therapies for the treatment of patients with mantle cell lymphoma.

Dr. Park on Emerging CAR T-Cell Therapies in Hematologic Malignancies

August 3rd 2021

Jae H. Park, MD, discusses emerging CAR T-cell therapies in hematologic malignancies.

Dr. Park on ​the Benefits of Off-the-Shelf CAR T-Cell Therapy in ALL

August 10th 2020

Jae Park, MD, discusses ​the benefits of off-the-shelf CAR T-cell therapy in acute lymphoblastic leukemia.

Dr. Park on Considerations of CAR T-Cell Therapy in Relapsed/Refractory ALL

August 7th 2020

Jae Park, MD, discusses considerations for CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia.

Dr. Park on Ongoing Research Efforts With CAR T-Cell Therapies in ALL

April 2nd 2020

Jae Park, MD, a hematologist oncologist at Memorial Sloan Kettering Cancer Center, discusses the use of CAR T-cell therapies in patients with acute lymphocytic leukemia.

Dr. Park on CD19-Directed CAR T-Cell Therapy in Patients With ALL

April 6th 2018

Jae Park, MD, hematologist oncologist, Memorial Sloan Kettering Cancer Center, discusses the potential of CD19-targeted chimeric antigen receptor (CAR) T-cell therapy in adult patients with acute lymphoblastic leukemia (ALL).

Dr. Jae Park on Impact of Disease Burden on CAR T-Cells in Relapsed B-ALL

June 10th 2016

Dr. Park on Using CD19-Targeted CAR T Cells as Treatment for ALL

December 16th 2014

Jae H. Park, MD, attending physician, Leukemia Service, Memorial Sloan Kettering Cancer Center, discusses a trial presented at the 2014 ASH Annual Meeting that explored CD19-targeted T cells as treatment for patients with relapsed, refractory B- cell ALL.